The results are so good that this trial will never run to the end, which is March. My bet is the FDA halts the trial and gives approval early to this drug. That's the risk of not being in MSTX or people shorting or selling it. This is all going to happen well before the March timeframe.
Not a buyer to be found and nothing but selling since the presentation started. Apparently some on this board must be misinterpreting the information, because the market seems to think this is a sell based on the presentation
Phase 3 results only a few months away for this blockbuster.
This looks very good.
IBB is up huge today. This stock rises nicely on 200K shares. It took 10,000 shares to run it back down to the lows of the day. Not a buyer to be found after his presentation.
You can almost bank on it. They've been waiting for this one and Ladenthal is the perfect spot to announce new findings, especially given the biotech storm we're in. The should be tremendous.
That would be a nice surprise for shorts.
Who said, other than this message board, that this company is entering any kind of market anytime soon? Let alone Q4 of this year? This company is years away from getting anything to market, aren't they?
well, you have to count the warrants as they will be dilutive. The strike on he warrants is $3.25 as clearly stated in the S1. When you add the warrants, you now have a share price of $2.16, which is why the stock is stuck down here. We are right at the price where the large investors are going to be getting it.
arcin, it was more of a question. I'm not certain myself, but I don't think they are coming any day now as one poster suggested.
Someone has to enlighten the board and tell us what is wrong with this stock. There's company's out there like ZIOP who don't even have Phase I trials yet and they are raging near their highs. TGTX is nothing but selling and more selling. The shorts are all over this one.
This is about as good as it gets and here we are drifting lower. Some of these companies aren't even in Phase I yet and they are trading better than TGTX. I know the shorts have to keep the pressure on, but I think it's astounding that there aren't any buyers for a company who saw one of it's competitors bought out for $26 Billion. No wonder the CEO said this company is way undervalued.
Selling upon selling. While the bios got crushed today, most of them recovered to only being down a percent or two my mid day. Not TGTX. It just keeps dropping and while the others rallied, it took a pause from selling, but never recovered like the others. This company had better news than any of the other hi flying candidates. FDA is cooperating with them and their drugs look exceptional. Who keeps selling?
Price target of $20
I don't know where all this selling has come from over the past few months, but let's see if these two presentations can help curb that selling.
If this doesn't tell you something is wrong, I don't know what does. I guess someone explained it well the other day. TGTX is in a crowded space and they have a long way to approval. Even if approved, who knows what the demand will be because the space is so crowded. Essentially, what they're working on is not needed.
Next catalyst is ASH in December. Other than that, you'd have to see interest from other companies for a buyout or something. Hard to imagine that PCYC could command $26 Billion and TGTX, with potentially a better and safer mix of drugs, isn't even worth a billion. Something is wrong with this picture and I guess we'll be the last to find out why.